Linda Ford, MD
Allergy & Immunology · Bellevue, NENPI 1003886813
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Cipla USA Inc. at 51.6% of the total. Reporting peaked in 2024 at $41,149 and has fallen 96.5% since, to $1,454 in 2025.
Across 381 payments — averaging $203.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cipla USA Inc.$40K
- Sanofi US Services Inc.$26K
- Sanofi$4K
- AstraZeneca$2K
- GSK$884
- Regeneron Healthcare Solutions, Inc.$705
- plus $4K from 32 others
Across 544 payments — averaging $4372.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$510K
- AstraZeneca$460K
- Sanofi US Services Inc.$279K
- Regeneron$255K
- Novartis$195K
- Sanofi$167K
- plus $513K from 8 others
What the payments were for
- Consulting fees$26,20834%
- Speaking & faculty fees$42,30254%
- Food & beverage$9,13912%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cipla USA Inc. | 1 | $40,052 |
| Sanofi US Services Inc. | 1 | $26,208 |
| Sanofi | 60 | $3,596 |
| AstraZeneca | 80 | $2,320 |
| GSK | 39 | $884 |
| Regeneron Healthcare Solutions, Inc. | 25 | $705 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $600 |
| Pharming Healthcare, Inc. | 27 | $431 |
| Amgen(2 entities) | 22 | $406 |
| Teva Pharmaceuticals USA, Inc. | 6 | $241 |
| Grifols Shared Services North America, Inc. | 2 | $237 |
| Grifols USA, LLC | 9 | $213 |
| Genentech USA, Inc. | 4 | $210 |
| Novartis | 10 | $194 |
| Lilly USA, LLC | 2 | $141 |
| Optinose US, Inc. | 7 | $117 |
| Biocryst US Sales Co., LLC | 7 | $115 |
| Incyte Corporation | 1 | $107 |
| Shire North American Group Inc | 5 | $96 |
| Kaleo, Inc. | 6 | $95 |
| CSL Behring | 5 | $93 |
| LEO Pharma Inc. | 5 | $88 |
| Boehringer Ingelheim | 5 | $79 |
| Pfizer | 2 | $71 |
| Octapharma USA, Inc. | 1 | $47 |
| ADMA Biomanufacturing LLC | 2 | $43 |
| Merck | 3 | $41 |
| Hospira, Inc. | 2 | $35 |
| Blueprint Medicines Corporation | 2 | $32 |
| Jubilant Hollisterstier LLC | 2 | $29 |
| Mylan Specialty L.p. | 2 | $24 |
| Verona Pharma, Inc. | 1 | $22 |
| Genentech, Inc. | 1 | $20 |
| Circassia Inc. | 1 | $18 |
| Alk-abello, Inc | 1 | $16 |
| Ionis Pharmaceuticals, Inc. | 1 | $14 |
| Organon | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$77,662 in reported general payments places this provider in the 85th percentile of 21 allergy & immunology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $31,021 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $4,981 |
| Fluticasone Propionate HfaFluticasone Propionate | 11 | $1,768 |
| Azelastine Hcl | 35 | $1,736 |
| Ventolin HfaAlbuterol Sulfate | 11 | $795 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $283 |
| Montelukast Sodium | 15 | $169 |
| Fluticasone Propionate | 19 | $124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $884 | $36,00254 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 21 allergy & immunology providers in Nebraska.
Other allergy & immunology in Bellevue
- Gregory BrooksBellevue$8K
- Kevin MurphyBoys Town$1.1M
- James TracyOmaha$104K
- Robert SzalewskiLincoln$78K
- Roger KobayashiOmaha$45K
- Mitchell PitlickOmaha$26K
- James FriedlanderOmaha$22K
- Brett KettelhutOmaha$21K
- Teodoro SeguraOmaha$8K
- Suzan PaeLincoln$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.